Browsing by Autor "Pedro I. Marti-Carvajal"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item type: Item , Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease(Elsevier BV, 2012) Arturo J Martí-Carvajal; Iván Solà; Pedro I. Marti-CarvajalNo randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease were identified. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade off between benefits and harms, we cannot recommend nor refute antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.Item type: Item , Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases(Elsevier BV, 2007) Arturo J Martí-Carvajal; Georgia Salanti; Pedro I. Marti-CarvajalWe found no evidence that human recombinant activated factor VII reduces the risk of death in patients with liver disease and upper gastrointestinal bleeding. However, we made our conclusion on a single randomised clinical trial. More randomised clinical trials having low risk of bias are necessary in order to determine the role of human recombinant factor VIIa in clinical practice.